BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 24755426)

  • 1. Structure-based design and synthesis of bicyclic fused-pyridines as MEK inhibitors.
    Lu H; Tu W; Fei H; Xu G; Hu Q; Zhang L; Lin B; Yuan J; Yin J; Gong A; Wan M; Wang D; Zhu X; Feng J; Wang Q; Sun P
    Bioorg Med Chem Lett; 2014 Jun; 24(11):2555-9. PubMed ID: 24755426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis and evaluation of novel 2-(1H-imidazol-2-yl) pyridine Sorafenib derivatives as potential BRAF inhibitors and anti-tumor agents.
    Jiao Y; Xin BT; Zhang Y; Wu J; Lu X; Zheng Y; Tang W; Zhou X
    Eur J Med Chem; 2015 Jan; 90():170-83. PubMed ID: 25461318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and evaluation of novel 2,4-diaminopyrimidines bearing bicyclic aminobenzazepines for anaplastic lymphoma kinase (ALK) inhibitor.
    Kang GA; Lee M; Song D; Lee HK; Ahn S; Park CH; Lee CO; Yun CS; Jung H; Kim P; Ha JD; Cho SY; Kim HR; Hwang JY
    Bioorg Med Chem Lett; 2015 Sep; 25(18):3992-8. PubMed ID: 26235945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of 1-(1H-Pyrazolo[4,3-c]pyridin-6-yl)urea Inhibitors of Extracellular Signal-Regulated Kinase (ERK) for the Treatment of Cancers.
    Lim J; Kelley EH; Methot JL; Zhou H; Petrocchi A; Chen H; Hill SE; Hinton MC; Hruza A; Jung JO; Maclean JK; Mansueto M; Naumov GN; Philippar U; Raut S; Spacciapoli P; Sun D; Siliphaivanh P
    J Med Chem; 2016 Jul; 59(13):6501-11. PubMed ID: 27329786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimization of allosteric MEK inhibitors. Part 2: Taming the sulfamide group balances compound distribution properties.
    Hartung IV; Hammer S; Hitchcock M; Neuhaus R; Scholz A; Siemeister G; Bohlmann R; Hillig RC; Pühler F
    Bioorg Med Chem Lett; 2016 Jan; 26(1):186-93. PubMed ID: 26611920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-based design, synthesis, and evaluation of imidazo[1,2-b]pyridazine and imidazo[1,2-a]pyridine derivatives as novel dual c-Met and VEGFR2 kinase inhibitors.
    Matsumoto S; Miyamoto N; Hirayama T; Oki H; Okada K; Tawada M; Iwata H; Nakamura K; Yamasaki S; Miki H; Hori A; Imamura S
    Bioorg Med Chem; 2013 Dec; 21(24):7686-98. PubMed ID: 24216091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design and synthesis of novel 3-sulfonylpyrazol-4-amino pyrimidines as potent anaplastic lymphoma kinase (ALK) inhibitors.
    Zhang P; Dong J; Zhong B; Zhang D; Yuan H; Jin C; Xu X; Li H; Zhou Y; Liang Z; Ji M; Xu T; Song G; Zhang L; Chen G; Meng X; Sun D; Shih J; Zhang R; Hou G; Wang C; Jin Y; Yang Q
    Bioorg Med Chem Lett; 2016 Apr; 26(8):1910-8. PubMed ID: 26979157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-based design and synthesis of imidazo[1,2-a]pyridine derivatives as novel and potent Nek2 inhibitors with in vitro and in vivo antitumor activities.
    Xi JB; Fang YF; Frett B; Zhu ML; Zhu T; Kong YN; Guan FJ; Zhao Y; Zhang XW; Li HY; Ma ML; Hu W
    Eur J Med Chem; 2017 Jan; 126():1083-1106. PubMed ID: 28039836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hybrids of MEK inhibitor and NO donor as multitarget antitumor drugs.
    Wang C; Xi D; Wang H; Niu Y; Liang L; Xu F; Peng Y; Xu P
    Eur J Med Chem; 2020 Jun; 196():112271. PubMed ID: 32305784
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition.
    Gilmartin AG; Bleam MR; Groy A; Moss KG; Minthorn EA; Kulkarni SG; Rominger CM; Erskine S; Fisher KE; Yang J; Zappacosta F; Annan R; Sutton D; Laquerre SG
    Clin Cancer Res; 2011 Mar; 17(5):989-1000. PubMed ID: 21245089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New class of azaheptapyridine FPT inhibitors as potential cancer therapy agents.
    Zhu HY; Desai J; Cooper AB; Wang J; Rane DF; Kirschmeier P; Strickland C; Liu M; Nomeir AA; Girijavallabhan VM
    Bioorg Med Chem Lett; 2014 Feb; 24(4):1228-31. PubMed ID: 24462667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pyrrole-3-carboxamides as potent and selective JAK2 inhibitors.
    Brasca MG; Nesi M; Avanzi N; Ballinari D; Bandiera T; Bertrand J; Bindi S; Canevari G; Carenzi D; Casero D; Ceriani L; Ciomei M; Cirla A; Colombo M; Cribioli S; Cristiani C; Della Vedova F; Fachin G; Fasolini M; Felder ER; Galvani A; Isacchi A; Mirizzi D; Motto I; Panzeri A; Pesenti E; Vianello P; Gnocchi P; Donati D
    Bioorg Med Chem; 2014 Sep; 22(17):4998-5012. PubMed ID: 25009002
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure based design of novel 6,5 heterobicyclic mitogen-activated protein kinase kinase (MEK) inhibitors leading to the discovery of imidazo[1,5-a] pyrazine G-479.
    Robarge KD; Lee W; Eigenbrot C; Ultsch M; Wiesmann C; Heald R; Price S; Hewitt J; Jackson P; Savy P; Burton B; Choo EF; Pang J; Boggs J; Yang A; Yang X; Baumgardner M
    Bioorg Med Chem Lett; 2014 Oct; 24(19):4714-4723. PubMed ID: 25193232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis, and biological evaluation of pyrazolopyrimidine-sulfonamides as potent multiple-mitotic kinase (MMK) inhibitors (part I).
    Zhang L; Fan J; Chong JH; Cesena A; Tam BY; Gilson C; Boykin C; Wang D; Aivazian D; Marcotte D; Xiao G; Le Brazidec JY; Piao J; Lundgren K; Hong K; Vu K; Nguyen K; Gan LS; Silvian L; Ling L; Teng M; Reff M; Takeda N; Timple N; Wang Q; Morena R; Khan S; Zhao S; Li T; Lee WC; Taveras AG; Chao J
    Bioorg Med Chem Lett; 2011 Sep; 21(18):5633-7. PubMed ID: 21798738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis, and evaluation of novel VEGFR2 kinase inhibitors: discovery of [1,2,4]triazolo[1,5-a]pyridine derivatives with slow dissociation kinetics.
    Oguro Y; Cary DR; Miyamoto N; Tawada M; Iwata H; Miki H; Hori A; Imamura S
    Bioorg Med Chem; 2013 Aug; 21(15):4714-29. PubMed ID: 23755884
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and biological evaluation of crown ether fused quinazoline analogues as potent EGFR inhibitors.
    Hu S; Xie G; Zhang DX; Davis C; Long W; Hu Y; Wang F; Kang X; Tan F; Ding L; Wang Y
    Bioorg Med Chem Lett; 2012 Oct; 22(19):6301-5. PubMed ID: 22959248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and biological evaluation of 2,3-diarylimidazo[1,2-a]pyridines as antileishmanial agents.
    Marhadour S; Marchand P; Pagniez F; Bazin MA; Picot C; Lozach O; Ruchaud S; Antoine M; Meijer L; Rachidi N; Le Pape P
    Eur J Med Chem; 2012 Dec; 58():543-56. PubMed ID: 23164660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis and evaluation of acridine derivatives as multi-target Src and MEK kinase inhibitors for anti-tumor treatment.
    Cui Z; Li X; Li L; Zhang B; Gao C; Chen Y; Tan C; Liu H; Xie W; Yang T; Jiang Y
    Bioorg Med Chem; 2016 Jan; 24(2):261-9. PubMed ID: 26707846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and Synthesis of Pyridazine Containing Compounds with Promising Anticancer Activity.
    Elmeligie S; Ahmed EM; Abuel-Maaty SM; Zaitone SA; Mikhail DS
    Chem Pharm Bull (Tokyo); 2017; 65(3):236-247. PubMed ID: 28250345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis and biological evaluation of novel 4-phenoxy-6,7-disubstituted quinolines possessing (thio)semicarbazones as c-Met kinase inhibitors.
    Zhai X; Bao G; Wang L; Cheng M; Zhao M; Zhao S; Zhou H; Gong P
    Bioorg Med Chem; 2016 Mar; 24(6):1331-45. PubMed ID: 26897090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.